Characteristic | High | Low | P value |
---|---|---|---|
Gender, n | |||
RSC | 156 | 96 | 0.3637 |
Male | 77 | 54 | |
Female | 77 | 42 | |
LSC | 68 | 106 | 0.1231 |
Male | 41 | 51 | |
Female | 27 | 55 | |
REC | 63 | 91 | 0.5118 |
Male | 37 | 48 | |
Female | 26 | 43 | |
MS, n | |||
RSC | 156 | 96 | < 0.0001* |
MSS/MSI-L | 92 | 89 | |
MSI-H | 64 | 7 | |
LSC | 68 | 106 | 0.0771 |
MSS/MSI-L | 64 | 105 | |
MSI-H | 4 | 1 | |
REC | 63 | 91 | 0.0264* |
MSS/MSI-L | 59 | 91 | |
MSI-H | 4 | 0 | |
Age,Mean ± SD | |||
RSC | 70 ± 13.69 | 67 ± 12.95 | 0.2222 |
LSC | 66 ± 11.11 | 64 ± 13.07 | 0.4267 |
REC | 64 ± 10.56 | 65 ± 12.32 | 0.81 |
Pathologic stage, n (%) | |||
RSC | 156 | 96 | 0.0278* |
I | 33(21.2%) | 11(11.5%) | |
II | 73(46.8%) | 38(39.6%) | |
III | 38(24.4%) | 32(33.3%) | |
IV | 12(7.7%) | 15(15.6%) | |
LSC | 68 | 106 | 0.1374 |
I | 12(17.6%) | 17(16.0%) | |
II | 26(38.2%) | 33(31.1%) | |
III | 23(33.8%) | 30(28.3%) | |
IV | 7(10.3%) | 26(24.5%) | |
REC | 63 | 91 | |
I | 10(15.9%) | 20(22.0%) | 0.0279* |
II | 29(46.0%) | 21(23.1%) | |
III | 17(27.0%) | 33(36.3%) | |
IV | 7(11.1%) | 17(18.7%) |